Holen Sie sich die Stockscreener-App
0.349
0.94%
-0.0111
Schlusskurs vom Vortag:
$0.36
Offen:
$0.3564
24-Stunden-Volumen:
59,338
Relative Volume:
0.10
Marktkapitalisierung:
$7.20M
Einnahmen:
$301.60K
Nettoeinkommen (Verlust:
$-8.22M
KGV:
-0.6903
EPS:
-0.5055
Netto-Cashflow:
$-5.05M
1W Leistung:
+2.80%
1M Leistung:
-0.97%
6M Leistung:
-71.47%
1J Leistung:
-71.70%
1-Tages-Spanne:
$0.3486
$0.3699
1-Wochen-Bereich:
$0.353
$0.391
52-Wochen-Spanne:
$0.3302
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
Firmenname
Nexalin Technology Inc
Sektor
Branche
Telefon
(832) 260-0222
Adresse
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.3498 | 7.41M | 301.60K | -8.22M | -5.05M | -0.5055 |
ABT
Abbott Laboratories
|
87.11 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.44 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
78.09 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.42 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.17 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Nexalin Technology Inc Aktie (NXL) Neueste Nachrichten
MSN Money - MSN
Nexalin reports sleep quality improvement in insomnia study By Investing.com - Investing.com Australia
Nexalin reports sleep quality improvement in insomnia study - Investing.com
After 4 weeks, Nexalin insomnia study showed no sham-group sleep gain - Stock Titan
Nexalin Technology, Inc. Announces Peer-Reviewed Publication with Neuroimaging Data Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia - marketscreener.com
Nexalin Technology appoints Justin Fleet as CFO - MSN
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Quantisnow
Nexalin Technology appoints Justin Van Fleet as CFO - MSN
Nexalin Technology slides after pricing $5M stock offering - MSN
Nexalin announces pivotal insomnia trial, targets Q2 enrollment By Investing.com - Investing.com India
NXL Nexalin Technology Q4 2025 earnings narrowly miss consensus estimates, shares tick higher as investors overlook minor shortfall.Expert Entry Points - Xã Thanh Hà
Nexalin Advances Pivotal Insomnia Trial for HALO Clarity - The Globe and Mail
NXL (Nexalin Technology Inc.) reports narrow Q4 2025 EPS miss, shares rise 18 percent on positive investor sentiment.Binary Event - Cổng thông tin điện tử tỉnh Tây Ninh
Nexalin (NXL) funds 160-patient pivotal HALO Clarity insomnia trial - Stock Titan
Nexalin announces pivotal insomnia trial, targets Q2 enrollment - Investing.com
Nexalin Technology, Inc. to Advance Pivotal Clinical Trial for HALO™ Clarity Device Aimed at Treating Moderate-to-Severe Insomnia - Quiver Quantitative
Nexalin lines up 160-patient insomnia study to support FDA filing - Stock Titan
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment - The Manila Times
NXL Forecast, Price Target & Analyst Ratings | NEXALIN TECHNOLOGY INC (NASDAQ:NXL) - ChartMill
Nexalin Technology : Investor Presentation March 2026 - marketscreener.com
Nexalin Technology (NXL) Stock: Why Growth Investors Chase It (-2.65%) 2026-04-20Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Lào Cai
Is Nexalin Technology (NXL) stock failing at resistance | Nexalin Technology posts 4.8% EPS miss, wider loss vs estimatesStability Report - Newser
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China - Sahm
Nexalin Technology (NXL) Advances Alzheimer's Clinical Strategy - GuruFocus
Nexalin Technology Advances Global Clinical Strategy for Alzheimer’s Treatment Following Key FDA Meetings - Quiver Quantitative
After FDA and China meetings, Nexalin reshapes Alzheimer’s study - Stock Titan
Nexalin Technology Inc: Plans to Submit an Am - Moomoo
Nexalin Technology, Inc. Advances FDA Alzheimer?S Strategy and Designs FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets - marketscreener.com
Exclusive: Nexalin study flags reduced self-injury in adolescents using brain stimulation device - MSN
What to Know About Nexalin Technology (NXL) Stock Today (Institutional Demand) 2026-04-15Target Price - Cổng thông tin điện tử tỉnh Tây Ninh
Nexalin Hosts Live Investor Webinar and Q&A - National Today
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 - The Manila Times
Macro Review: Whats next for Nexalin Technology Inc Equity Warrant stock2026 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
Targets Report: Why is Nexalin Technology Inc Equity Warrant stock going upQuarterly Profit Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Hedge Fund Moves: Is Nexalin Technology Inc still a buy after recent gains2026 Retail Activity & Low Drawdown Trading Strategies - baoquankhu1.vn
EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device - Sahm
Are investors bearish on Nexalin Technology (NXL) Stock | Price at $0.39, Up 1.32%Community Pattern Alerts - Newser
Hedge Fund Moves: What analysts say about Nexalin Technology Inc stock2026 Price Swings & Daily Price Action Insights - baoquankhu1.vn
Profit Review: Whats next for Nexalin Technology Inc Equity Warrant stock2026 Short Interest & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents - Bitget
Nexalin Technology, Inc. Reports Significant Reductions in Self-Injury Behaviors and Depressive Symptoms in BMC Psychiatry Publication on DIFS Approach - Quiver Quantitative
Nexalin teen pilot finds noninvasive brain stimulation cut self-harm - Stock Titan
Levels Update: Will Nexalin Technology Inc benefit from geopolitical trends2026 EndofYear Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
NXL SEC FilingsNexalin Tech 10-K, 10-Q, 8-K Forms - Stock Titan
Maxim Group Maintains Nexalin Technology(NXL.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
Finanzdaten der Nexalin Technology Inc-Aktie (NXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):